Making Sense of the Long Term Care Mega Rule: Unnecessary Drugs & Psychotropics. Session Objectives. January 2018

Size: px
Start display at page:

Download "Making Sense of the Long Term Care Mega Rule: Unnecessary Drugs & Psychotropics. Session Objectives. January 2018"

Transcription

1 Making Sense of the Long Term Care Mega Rule: Unnecessary Drugs & Psychotropics Bridget McCrate Protus, PharmD, MLIS, BCGP, CDP Director of Drug Information Optum Hospice Pharmacy Services Session Objectives Summarize LTC Requirements of Participation with focus on psychotropics medication Discuss impact on hospice care within LTC facilities Review patient care scenarios 2 All Rights Reserved 1

2 Providing Hospice Care in LTC Facilities About 40% of hospice care is provided for patients in nursing facilities 1 About 4% of LTC residents with Alzheimer s disease receive hospice care 2 LTC facilities operate under heavy regulation 1 NHPCO Facts & Figures, CDC FastStats Alzheimer s disease 3 Reform of Requirements for Long-Term Care AKA Mega Rule or RoP First major update to LTC regulations since CFR Parts 40, 431, 447, 482, 483, 48, 488, & CFR (d) Pharmacy Services Hospice care is fully integrated into regulatory & interpretive guidance No hospice exceptions 3 Federal Register, All Rights Reserved 2

3 Reform of Requirements for Long-Term Care State Operations Manual (SOM) Interpretive Guidance appendix PP Document written by CMS containing the regulations and guidelines that govern nursing facilities Used as the basis for the survey process to assist surveyors in evaluating compliance with CMS standards F tags & citing deficiencies Classification system to categorize sections of the SOM IG explaining the regulatory requirements Surveyors finding issues with compliance cite by the F tag 3 Federal Register, 2016 Mega Rule Implementation Phases 3 Phase 1 Phase 2 Phase 3 Effective: November 28, 2016 Final Rule effective date Planned implementation in 3 phases Regulatory language updates New reporting process for medication irregularities to the nursing home s medical director Facility must have P&P for Drug Regimen Review Effective: November 28, 2017 Revised SOM IG released Updated psychotropics definition All psychotropics held to 14d PRN with rationale & duration Antipsychotics 14d PRN limit, no renewal & resident evaluation before new PRN order QAPI, ABX, Med errors Effective: November 28, 2019 Requirements that need more time to implement Additional QAPI & ABX stewardship components Implementing trauma informed care Compliance & ethics program 4 LAO, All Rights Reserved 3

4 Reform of Requirements for Long-Term Care Phase 2 implementation Majority of Pharmacy Services components Title F Tag Old Tag Drug Regimen Review F76 F428 Unnecessary Drugs F77 F329 Psychotropic Drugs F78 F329 / F428 Medication Errors F79 F760 F332 F333 7 Regulation (CFR) versus Guidance (SOM) Regulation (F tag) Word Count (CFR v SOM) Drug Regimen Review (F76) CFR: 28 words SOM Interpretive Guidance for just these Unnecessary Drugs (F77) CFR: 80 words sections Psychotropic Drugs (F78) Medication Errors (F79/F760) CFR: 190 words CFR: 3 words Word Count Totals 90 words > 1,000 words All Rights Reserved 4

5 Regulation (CFR) versus Guidance (SOM IG) CFR wording is pretty sparse SOM IG provides the context and intent Standards of practice Patient centered care Resources and tools Must vs Should Must comply with the regulations, this is how you should do it Risk reduction Is there evidence to support the practice/treatment? Does the benefit outweigh the risk? Was the resident/family involved in the decision making? 9 Unnecessary Drugs (F77) All Rights Reserved

6 Unnecessary Drugs (F77) 1. Inadequate indications for use 2. Inadequate monitoring 3. Excessive dose 4. Excessive duration. Adverse consequences Permission given by or a request made by the resident and/or representative does not serve as a sole justification for the medication itself. 11 Unnecessary Drugs (F77) inadequate indications for use failure to provide a clinically pertinent rationale, failure to attempt non pharmacological approaches, failure to consider other factors (infection, dehydration) that may be contributing to the resident s expression of distress Example: Mrs. Jones is prescribed Ditropan (oxybutynin) for urinary incontinence Other causes ruled out before prescribing?» Side effects from other drugs, infection, ambulation difficulty Assistance with toileting attempted? 12 All Rights Reserved 6

7 Unnecessary Drugs (F77) inadequate monitoring failure to monitor response to medication, lack of progression towards therapeutic goal, failure to consider worsening symptoms may be related to a medication, failure to monitor effectiveness of non pharmacological approaches before prescribing medications Example: Mrs. Jones is prescribed Ditropan (oxybutynin) for urinary incontinence If oxybutynin started, did the incontinence improve? Is Mrs. Jones satisfied with the improvement? Is Mrs. Jones experiencing any side effects (dry mouth, constipation, confusion)? How did Mrs. Jones respond to toileting assistance? 13 Unnecessary Drugs (F77) excessive dose giving any amount of medication that exceeds manufacturer s recommendations or clinical practice guidelines, or standards of practice without documented clinically pertinent rationale, failure to consider continued necessity or possibility to taper the medication Example: Mrs. Jones is prescribed Ditropan (oxybutynin) for urinary incontinence Recommended dose is mg BID to TID, lower for elderly» Why is Mrs. Jones dose 10mg Q6AM and Q6PM?» Would a lower, more frequent dosing strategy be better? 14 All Rights Reserved 7

8 Unnecessary Drugs (F77) excessive duration continuation of a medication after desired therapeutic goal is achieved without evaluating if there is a continued need for the medication Example: Mrs. Jones is prescribed Ditropan (oxybutynin) for urinary incontinence How long has she been taking this medication? Should she continue oxybutynin forever? 1 Unnecessary Drugs (F77) adverse consequences failure to act upon or report presence of adverse consequences, failure to monitor for presence of adverse consequences (especially high risk medications) Example: Mrs. Jones is prescribed Ditropan (oxybutynin) for urinary incontinence Is Mrs. Jones experiencing any side effects (dry mouth, constipation, confusion)?» If yes, was a dose reduction attempted?» If yes, why is she still taking the medication? Would another medication be as effective, but safer for Mrs. Jones? 16 All Rights Reserved 8

9 Psychotropic Medications (F78) Psychotropic Medications (F78) any drug that affects brain activities associated with mental processes and behavior includes, but is not limited to*, 4 broad categories: Antidepressants Anxiolytics Hypnotics Antipsychotics (Other*) 18 All Rights Reserved 9

10 Psychotropic Medications (F78) 19 Psychotropic Medications: PRN Requirements Category Examples* PRN Requirements Antidepressants sertraline (Zoloft) citalopram (Celexa) duloxetine (Cymbalta) amitriptyline (Elavil) nortriptyline (Pamelor) trazodone (Desyrel) Anxiolytics Hypnotics alprazolam (Xanax) lorazepam (Ativan) diazepam (Valium) hydroxyzine (Atarax) clorazepate (Tranxene) zolpidem (Ambien) temazepam (Restoril) suvorexant (Belsomra) eszopiclone (Lunesta), phenobarbital 14 day limit on PRN orders PRN order may be extended if the attending physician or prescriber believes it is appropriate to extend the order Rationale for extended time period must be documented in the medical record and must indicate a specific duration *Note: the Interpretive Guidelines do not provide specific medication examples for each category of psychotropics; medications above are commonly prescribed examples. This is not intended to be a comprehensive list. 20 All Rights Reserved 10

11 Antipsychotics & PRN Requirements Category Examples* PRN Requirements Antipsychotics haloperidol (Haldol) 14 day limit on PRN orders quetiapine (Seroquel) olanzapine (Zyprexa) ziprasidone (Geodon) aripiprazole (Abilify) prochlorperazine (Compazine) chlorpromazine (Thorazine) If attending physician or prescriber wants to write a new order for the PRN antipsychotic, the attending physician or prescriber must evaluate the resident to determine if the order for a PRN antipsychotic is appropriate *Note: the Interpretive Guidelines do not provide specific medication examples for each category of psychotropics; medications above are commonly prescribed examples. This is not intended to be a comprehensive list. 21 Additional Antipsychotic PRN Info As part of the evaluation, the attending physician or prescribing practitioner should, at a minimum, determine and document the following in the resident s medical record: Is the antipsychotic medication still needed on a PRN basis? What is the benefit of the medication to the resident? Have the resident s expressions or indications of distress improved as a result of the PRN medication? Note: Report of the resident s condition from facility staff to the attending physician or prescribing practitioner does not constitute an evaluation. 22 All Rights Reserved 11

12 The Big Other any drug that affects brain activities associated with mental processes and behavior includes, but is not limited to Examples of Other CNS Active Medications Antihistamines Diphenhydramine (Benadryl), dimenhydrinate (Dramamine), cyproheptadine (Periactin) Anti epileptic drugs Anti Parkinson s drugs Muscle relaxants Newer Non Antipsychotics Gabapentin (Neurontin), valproate (Depakote), topiramate (Topamax), pregabalin (Lyrica) Ropinirole (Requip), pramipexole (Mirapex), amantadine Tizanidine (Zanaflex), cyclobenzaprine (Flexeril), carisoprodol (Soma) Pimavanserin (Nuplazid), Quinidine DXM (Neudexta) 23 Scenario 1 Psychotropics Mrs Jones Med List Sertraline (Zoloft) 100mg PO daily for depression GDR required within the first year after resident is admitted on a psychotropic or after initiation of a psychotropic, the facility must attempt a GDR in two separate quarters (at least one month between attempts). After the first year, GDR must be attempted annually, unless clinically contraindicated. Stepwise tapering to see if symptoms can be managed by a lower dose or med can be d/c d Clinically contraindicated target symptoms returned or worsened after GDR + physician documents why additional GDR attempts might impair function or increase distress Non pharm, adequate monitoring for effectiveness and adverse consequences Sertraline 100mg PO daily for depression Lorazepam 0.mg PO Q6H PRN for anxiety Quetiapine 0mg PO Q12H for dementia related behaviors Quetiapine 0mg PO Q6H PRN for agitation 24 All Rights Reserved 12

13 Scenario 1 Psychotropics Mrs Jones Med List Lorazepam (Ativan) 0.mg PO Q6H PRN anxiety Prescriber must document diagnosed condition and indication for PRN Time limited to 14 day PRN from initiation Order can be extended past initial 14 day period Prescriber must document rationale for extending PRN use past 14 days and indicate specific duration Sertraline 100mg PO daily for depression Lorazepam 0.mg PO Q6H PRN for anxiety Quetiapine 0mg PO Q12H for dementia related behaviors Quetiapine 0mg PO Q6H PRN for agitation 2 Scenario 2 Antipsychotics Mrs Jones Med List Quetiapine (Seroquel) 0mg PO Q12H for dementia related behaviors (harm to self/others) GDR required within the first year after resident is admitted on a psychotropic or after initiation of a psychotropic, the facility must attempt a GDR in two separate quarters (at least one month between attempts). After the first year, GDR must be attempted annually, unless clinically contraindicated. Stepwise tapering to see if symptoms can be managed by a lower dose or med can be d/c d Clinically contraindicated target symptoms returned or worsened after GDR + physician documents why additional GDR attempts might impair function or increase distress Multiple non pharm interventions in care plan, adequate monitoring for effectiveness and adverse consequences Sertraline 100mg PO daily for depression Lorazepam 0.mg PO Q6H PRN for anxiety Quetiapine 0mg PO Q12H for dementia related behaviors Quetiapine 0mg PO Q6H PRN for agitation 26 All Rights Reserved 13

14 Scenario 2 Antipsychotics Mrs Jones Med List Quetiapine (Seroquel) 0mg PO Q6H PRN for agitation* Prescriber must document diagnosed condition and indication for PRN Time limited to 14 day PRN from initiation No new order for PRN quetiapine unless prescriber evaluates Mrs Jones to determine if a new quetiapine needed on PRN basis Benefit of quetiapine to Mrs Jones Has Mrs Jones distress improved as a result of PRN quetiapine *agitation is not sufficient as diagnosis, must be specific Sertraline 100mg PO daily for depression Lorazepam 0.mg PO Q6H PRN for anxiety Quetiapine 0mg PO Q12H for dementia related behaviors Quetiapine 0mg PO Q6H PRN for agitation 27 Scenario 3 What About Seizures? Mr Smith Med List Levetiracetam (Keppra) 1000mg PO Q12H Lorazepam 2mg PR Q1mins PRN breakthrough seizure, MRx3, max dose 8mg Both orders are for psychotropics but both have clear clinical indication GDR not typically indicated per best practice & clinical need for levetiracetam to control Mr Smith s seizures* Lorazepam PRN orders to stop acute seizure also has clinical need for use extended past 14 days and prescriber should document expected duration of need (6 months for hospice patient is reasonable) *still need to consider if this is correct dose & when was last documented seizure Levetiracetam 1000mg PO Q 12H Lorazepam 2mg PR Q 1 minutes PRN breakthrough seizure, may repeat 3 times, max dose 8mg 28 All Rights Reserved 14

15 Challenge or Opportunity? Opportunity to build relationships Change in practice will be required Don t push to work around the regs Innovate to work within the regs Develop a hospice team member as LTC liaison 29 Recently Announced Enforcement Delay Enforcement postponed until May 2019 for some components of Phase 2 (includes F78) Surveyors will still cite for noncompliance 18 month moratorium to learn and adapt 30 All Rights Reserved 1

16 Key Points Mega Rule is much more than psychotropic restrictions No hospice exceptions, hospice is fully integrated No published lists of target meds Implementation of Phase 2 just started on November 28, 2017, expect to see interpretations evolve over time 31 References 1. National Hospice & Paliative Care Organization (NHPCO). NHPCO Facts & Figures: Hospice Care in America, 2016 edition. Alexandria, VA:NHPCO; September Accessed December 12, National Center for Health Statistics. FastStats Alzheimer s disease. October 6, Atlanta, GA:CDC/National Center for Health Statistics. Accessed December 12, Centers for Medicare & Medicaid Services (CMS). Medicare and Medicaid Programs; reform of requirements for long term care facilities. Federal Register 2016;81(192): Available at /pdf/ pdf Accessed October 19, LeadingAge Ohio. Medicare and Medicaid Programs; Reform of requirements for long erm care facilities. Final Rule summary. Available at Accessed December 13, Centers for Medicare & Medicaid Services (CMS). Publication State Operations Manual (SOM) Appendix PP Guidance to Surveyors for Long Term Care Facilities. Rev 173, Available at: and Guidance/Guidance/Manuals/downloads/som107ap_pp_guidelines_ltcf.pdf Accessed December 13, Centers for Medicare & Medicaid Services (CMS). Survey & Certification. Guidance to Laws & Regulations. Nursing Homes. Enrollment and Certification/GuidanceforLawsAndRegulations/Nursing Homes.html Accessed October 19, Requirements for States and Long Term Care Facilities. Subpart B Requirements for long term care facilities. Pharmacy Services. 42 CFR Accessed December 12, All Rights Reserved 16

17 Thank You! Bridget McCrate Protus, PharmD, MLIS, BCGP, CDP Director of Drug Information Hospice Pharmacy Services All Rights Reserved 17

The Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State

The Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State The Basics of Psychoactive/Psychotropic Medications Tina Sanchez, RN, SMQT New Mexico Department of Health Division of Health Improvement State RAI/MDS Coordinator Objectives Upon completion of this training,

More information

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017

Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017 Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic

More information

2/12/2016. Drugs and Dementia in the Hospice Patient. Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources

2/12/2016. Drugs and Dementia in the Hospice Patient. Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources Drugs and Dementia in the Hospice Patient Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources 1 Drug Therapy: Targeted at Symptoms Cognitive: Impaired abstract thinking Impaired

More information

Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines

Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding

More information

Pharmacy Related Regulatory Changes in LTC. By: Anastasia Sidor, PharmD, BCGP Consultant Pharmacist Director Brockie Pharmatech

Pharmacy Related Regulatory Changes in LTC. By: Anastasia Sidor, PharmD, BCGP Consultant Pharmacist Director Brockie Pharmatech Pharmacy Related Regulatory Changes in LTC By: Anastasia Sidor, PharmD, BCGP Consultant Pharmacist Director Brockie Pharmatech Objectives 1. Contrast the difference between regulation and guidance within

More information

Have You Ever Wondered

Have You Ever Wondered Have You Ever Wondered A few facts about medication use and related falls The Number of Medications You Take & The Connection to Falls CONCERN: As you increase the number of medications that you take,

More information

PSYCHIATRY INTAKE FORM

PSYCHIATRY INTAKE FORM Please complete all information on this form. PSYCHIATRY INTAKE FORM Name Date Date of Birth Primary Care Physician Current Therapist/Counselor What are the problem(s) for which you are seeking help? 1.

More information

Antipsychotics for Dementia Under Control or Over-Prescribed?

Antipsychotics for Dementia Under Control or Over-Prescribed? Antipsychotics for Dementia Under Control or Over-Prescribed? Nathaniel Hedrick, PharmD ProCare HospiceCare, Manager of Clinical Services Learning Objectives Summarize the disease progression and most

More information

Richard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA

Richard Heidenfelder M.D. Child, Adolescent and Adult Psychiatry 447 9th Ave San Diego, CA *We are not accepting any New Patients who are currently taking any controlled pain medications *We are *Note: not completion accepting of the any following New Patients paperwork who and Initial are Screening

More information

Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA

Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA Psychotropic Medications Archana Jhawar, PharmD, BCPP Clinical Faculty of UIC Pharmacy Practice Clinical Psychiatric Pharmacist Jesse Brown VA Goals of Medications Use least number at lowest dose to get

More information

Medications and Children Disorders

Medications and Children Disorders Mental Health Comprehensive Services Providing Family Stability and Developing Life Coping Skills Medications and Children Disorders Psychiatric medications can be an effective part of the treatment for

More information

Study Guidelines for Quiz #1

Study Guidelines for Quiz #1 Annex to Section J Page 1 Study Guidelines for Quiz #1 Theory and Principles of Psychopharmacology, Classifications and Neurotransmitters, Anxiolytics/Antianxiety/Minor Tranquilizers, Stimulants, Nursing

More information

Psychotropic Medication. Including Role of Gradual Dose Reductions

Psychotropic Medication. Including Role of Gradual Dose Reductions Psychotropic Medication Including Role of Gradual Dose Reductions What are they? The phrase psychotropic drugs is a technical term for psychiatric medicines that alter chemical levels in the brain which

More information

OBJECTIVES. Achieving Success in Reducing Inappropriate Use of Antipsychotic Medication in Patients with Dementia

OBJECTIVES. Achieving Success in Reducing Inappropriate Use of Antipsychotic Medication in Patients with Dementia Achieving Success in Reducing Inappropriate Use of Antipsychotic Medication in Patients with Dementia Amy J. Osborn, NHA, PMP Executive Director, Health Services Advisory Group (HSAG) Rick Foley, PharmD,

More information

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*

COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150

More information

Ativan and geodon compatibility

Ativan and geodon compatibility P ford residence southampton, ny Ativan and geodon compatibility In this case, a patient developed severe hypotension (66/30 mm Hg) after receiving intramuscular olanzapine and intramuscular lorazepam

More information

Appendix: Psychotropic Medication Reference Tables

Appendix: Psychotropic Medication Reference Tables Appendix: Psychotropic Medication Reference Tables How to Use these Tables These reference tables are designed to provide clinic staff with specific medication related criteria for the Polypharmacy, Cardiometabolic

More information

Medicine Related Falls Risk Assessment Tool (MRFRAT)

Medicine Related Falls Risk Assessment Tool (MRFRAT) Medicine Related Falls Risk Assessment Tool (MRFRAT) The Medicine Related Falls Risk Assessment tool (MRFRAT) in Appendix 1 is designed to help identify patients at risk of falls due to their current medicine

More information

Katee Kindler, PharmD, BCACP

Katee Kindler, PharmD, BCACP Speaker Introduction Katee Kindler, PharmD, BCACP Current Practice: Clinical Pharmacy Specialist Ambulatory Care, St. Vincent Indianapolis Assistant Professor of Pharmacy Practice, Manchester University,

More information

AAA. add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders

AAA. add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders AAA Adolescents & Adults with Autism A Study of Family Caregiving add dan campbell artwork cats? Report #12 Changes in Medication Use over Time in Adolescents and Adults with Autism Spectrum Disorders

More information

It is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:

It is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met: Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important

More information

Geriatric Pharmacology. Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center

Geriatric Pharmacology. Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center Geriatric Pharmacology Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center Silver Tsunami 2010: 40 million (13%) 2030: 72 million (20%) Baby Boomers (1946-1964)

More information

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis

Psychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious

More information

Management of Delirium in Hospice Patients

Management of Delirium in Hospice Patients Presentation Objectives Management of Delirium in Hospice Patients Lynn Williams, BSPharm Clinical Pharmacist Hospice Pharmacy Solutions Identify the clinical features of delirium Understand the underlying

More information

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance

More information

New Patient Questionnaire

New Patient Questionnaire 4 Embarcadero Center, Suite 1400, San Francisco, CA 94111 (415) 926-7774 phone; (415) 591-7760 office@sanfranciscopsych.com New Patient Questionnaire Thank you for trusting San Francisco Psychiatry with

More information

NorthSTAR. Pharmacy Manual

NorthSTAR. Pharmacy Manual NorthSTAR Pharmacy Manual Revised October, 2008 Table of I. Introduction II. III. IV. Antidepressants New Generation Antipsychotic Medications Mood Stabilizers V. ADHD Medications VI. Anxiolytics and Sedative-Hypnotics

More information

Guide to Psychiatric Medications for Children and Adolescents

Guide to Psychiatric Medications for Children and Adolescents Guide to Psychiatric Medications for Children and Adolescents by Glenn S. Hirsch, M.D. The following guide includes most of the medications used to treat child and adolescent mental disorders. It lists

More information

Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials

Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials SPEAKER NOTES Overview and Update on Current Psychopharmacological Medications, Including New Medications in Clinical Trials Summarized by Thomas T. Thomas New psychotropic medications are coming on the

More information

Updates to CMS SOM rules on Psychosocial Issues, Deficiency Categorization, and Psychotropic Medication Use

Updates to CMS SOM rules on Psychosocial Issues, Deficiency Categorization, and Psychotropic Medication Use Updates to CMS SOM rules on Psychosocial Issues, Deficiency Categorization, and Psychotropic Medication Use Stephen Eide R. Ph Oni Kinberg LCSW, MSSW Updates to the SOM On March 25, 2016 CMS sent out updates

More information

TRANSCRANIAL MAGNETIC STIMULATION & BRAIN MUSIC THERAPY

TRANSCRANIAL MAGNETIC STIMULATION & BRAIN MUSIC THERAPY TMS - DEPRESSION HISTORY Date: Patient Name: DOB: How did you hear about TMS? What do you know about TMS? Referring Physician? Name of Practice: Name of Inpatient Treatment for Depression: Name of Inpatient

More information

Psychotropic Strategies Handout Package

Psychotropic Strategies Handout Package Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles

More information

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused

Treat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines

More information

Behavioral Health Evaluation

Behavioral Health Evaluation This document is intended to serve as a template for a behavioral health committee meeting in an extended care facility. The State Operations Manual (SOM), Appendix PP - "Guidance to Surveyors for Long

More information

Treatments for Alzheimer s Disease A Quick Guide for Patients and Caregivers

Treatments for Alzheimer s Disease A Quick Guide for Patients and Caregivers Treatments for Alzheimer s Disease A Quick Guide for Patients and Caregivers By Kelsey F. Lee, PharmD candidate 2011 Preceptor: Demetra Antimisiaris, PharmD University of Louisvlle Dept. Family Medicine

More information

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer

PSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally

More information

Psychiatric Distress in Chronic & Terminal Illness Barb Henry, ARNP, MSN

Psychiatric Distress in Chronic & Terminal Illness Barb Henry, ARNP, MSN Psychiatric Distress in Chronic & Terminal Illness Barb Henry, ARNP, MSN Psycho-Oncology Consultants, LLC & The University of Cincinnati Central Clinic University of Cincinnati Central Clinic www.centralclinic.org

More information

Supplement: Tables and Figures

Supplement: Tables and Figures Supplement: Tables and Figures Supplement Table 1. Baseline Characteristics by Study and Efavirenz Assignment Supplement Table 2. Baseline Psychoactive Medications by Efavirenz Assignment* Supplement Table

More information

Antipsychotic use in Dementia care. Jabbar Fazeli, MD

Antipsychotic use in Dementia care. Jabbar Fazeli, MD Antipsychotic use in Dementia care Jabbar Fazeli, MD www.mainegeriatrics.com What changed in 2012? NY times- May 9, 2011!! Antipsychotic Drugs Called Hazardous for the Elderly - referencing the OIG audit

More information

NEW PATIENT INTAKE FORM

NEW PATIENT INTAKE FORM NEW PATIENT INTAKE FORM Please fill out the following form to the best of your ability. Some sections may not apply to you. We will discuss your responses in greater detail during your first appointment.

More information

Clinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.

Clinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08. Clinical Policy: (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy for important

More information

Medications Contributing to Falls. Kate Niemann, PharmD BCGP AuBurn Pharmacy

Medications Contributing to Falls. Kate Niemann, PharmD BCGP AuBurn Pharmacy Medications Contributing to Falls Kate Niemann, PharmD BCGP AuBurn Pharmacy Why Are Falls Important? Leading cause of injury in elders Costs to the system (CDC, 2008) ER Visits: 2.2 million $28.2 billion

More information

Mental Health Intake Form

Mental Health Intake Form Current Symptoms Checklist: (check once for any symptoms present, twice for major symptoms) ( ) ( ) Depressed mood ( ) ( ) Racing thoughts ( ) ( ) Excessive worry ( ) ( ) Unable to enjoy activities ( )

More information

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course)

Review of Psychotrophic Medications. (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Review of Psychotrophic Medications (An approved North Carolina Division of Health Services Regulation Continuing Education Course) Common Psychiatric Disorders *Schizophrenia *Depression *Bipolar Disorder

More information

Medications, By Class, in TBI

Medications, By Class, in TBI Medications, By Class, in TBI Generic/Brand Name Drawback Advantage Mood Stabilizers (anti-seizure medications) Carbamazepine (Carbatrol ) (Equetro ) (Tegretol ) Gabapentin (Neurontin ) Lamotrigine (Lamictal

More information

Happy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care?

Happy Daisy Ltd. New Client intake Form. What are the issues for which you are seeking care? Happy Daisy Ltd. New Client intake Form Name Date Preferred name Pronouns Referred by Date of birth Age Race What are the issues for which you are seeking care? 1. 2. 3. Please check of any of the symptoms

More information

Psychiatric Medication Guide

Psychiatric Medication Guide Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants

More information

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies

4/2/13 COMMON CLASSES OF MEDICATIONS. Child & Adolescent Behavioral Medicine & Medication Therapies. Behavioral Medicine & Medication Therapies Child & Adolescent Behavioral Medicine & Medication Therapies Brian J Cowles, PharmD Associate Professor of Pharmacy Practice Albany College of Pharmacy & Health Sciences; Vermont Campus Behavioral Medicine

More information

Learning Objectives. Delirium. Delirium. Delirium. Terminal Restlessness 3/28/2016

Learning Objectives. Delirium. Delirium. Delirium. Terminal Restlessness 3/28/2016 Terminal Restlessness Dr. Christopher Churchill St. Cloud VA Health Care System EC&R Service Line Director & Medical Director Hospice & Palliative Care March 31, 2016 Learning Objectives Different Terminology

More information

Policy Evaluation: Low Dose Quetiapine Safety Edit

Policy Evaluation: Low Dose Quetiapine Safety Edit Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Vraylar) Reference Number: CP.PMN.91 Effective Date: 11.16.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Answer. Answer. Question. Question 6/4/2018. Symptom Management Quiz Show

Answer. Answer. Question. Question 6/4/2018. Symptom Management Quiz Show I can t breathe! That stinks! Ouch! You make me sick! Leave me alone! I can t breathe! That stinks! Ouch! You make me sick! Leave me alone! Symptom Management Quiz Show Bridget McCrate Protus, PharmD,

More information

Objectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition

Objectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition Reducing the Use of Antipsychotics in Long Term Care Communities Alan W. Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy Objectives Recognize the clinical evidence for the need to change

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Invega) Reference Number: CP. PMA.10.11.19 Effective Date: 10.06.16 Last Review Date: 04.18 Line of Business: CenpaticoMedicaid Revision Log See Important Reminder at the end of this

More information

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned

More information

Mental Health Intake Form

Mental Health Intake Form 38600 Van Dyke Ave., Suite 200 Sterling Heights, MI 48313 Phone: (586) 933-5395 Fax: (586) 935-0159 Mental Health Intake Form Please complete all information on this form and bring it to the first visit.

More information

Schedule FDA & literature based indications

Schedule FDA & literature based indications Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for

More information

Anthony J. Caprio, MD, CMD, AGSF 1

Anthony J. Caprio, MD, CMD, AGSF 1 Objectives 1) Discuss the dangers of polypharmacy 2) Review potentially inappropriate medications for older adults Doc, I think I am taking too many medications! 3) Develop strategies for prioritizing

More information

MO Medicaid Foster Care Drugs FY10-FY14

MO Medicaid Foster Care Drugs FY10-FY14 MO Medicaid Foster Care Drugs FY10-FY14 Medicaid (MO HealthNet) Cost of Drugs given to Missouri Foster Care Children by combinations of Age, Gender, Drug Class and Fiscal Year [Raw Data Provided by Missouri

More information

NURSING HOME MEDICINE UPDATE

NURSING HOME MEDICINE UPDATE NURSING HOME MEDICINE UPDATE - 2018 Bryan Primary Care Conference, Spring 2018 DISCLOSURES No financial disclosures I will mention non-fda approved use of medications OBJECTIVES 1. Review the new CMS rules

More information

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

MEDICATION ALGORITHM FOR ANXIETY DISORDERS Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON

More information

The Ins and Outs of PD Meds. Johanna Hartlein, APRN, MSN Family Nurse Practitoner and Great Hugger Washington University School of Medicine

The Ins and Outs of PD Meds. Johanna Hartlein, APRN, MSN Family Nurse Practitoner and Great Hugger Washington University School of Medicine The Ins and Outs of PD Meds Johanna Hartlein, APRN, MSN Family Nurse Practitoner and Great Hugger Washington University School of Medicine Words of Caution Just because I list a possible side effect, it

More information

Understanding Alzheimer s Disease

Understanding Alzheimer s Disease Understanding Alzheimer s Disease Alzheimer s disease is an irreversible, progressive brain disorder that slowly impacts memory, thinking, skills and, eventually, the ability to carry out the simplest

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lyrica) Reference Number: ERX.NPA.10 Effective Date: 06.01.15 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the

More information

Steps for Initiating Electroconvulsive Therapy Treatment

Steps for Initiating Electroconvulsive Therapy Treatment Steps for Initiating Electroconvulsive Therapy Treatment PSYCHIATRISTS CAN REFER PATIENTS FOR ECT TREATMENT AT EL CAMINO HOSPITAL BY CALLING THE ECT NURSE COORDINATOR AT 650-962-5795. Once the referral

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Saphris) Reference Number: CP.PMN.15 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder

More information

The Path to Geriatric Sensitive Evidence - Based Care: Medications and Older Adults Barberton Hospital. Joyce Restifo MSN, RN Geriatric CNS-BC

The Path to Geriatric Sensitive Evidence - Based Care: Medications and Older Adults Barberton Hospital. Joyce Restifo MSN, RN Geriatric CNS-BC The Path to Geriatric Sensitive Evidence - Based Care: Medications and Older Adults Barberton Hospital Joyce Restifo MSN, RN Geriatric CNS-BC Aging Population By 2030, older adults will make up 20% of

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy

More information

Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay

Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay Medicine Related Falls Risk Assessment Tool (MrFRAT) User Guide for Age Related Residential Care Facility Staff in Hawke s Bay (Revised edition November 2015) The Medicine Related Falls Risk Assessment

More information

Delirium, Dementia, and Amnestic Disorders. Dr.Al-Azzam 1

Delirium, Dementia, and Amnestic Disorders. Dr.Al-Azzam 1 Delirium, Dementia, and Amnestic Disorders Dr.Al-Azzam 1 Introduction Disorders in which a clinically significant deficit in cognition or memory exists The number of people with these disorders is growing

More information

Psychoactive Medications. Alya Reeve, MD Carla Fedor, RN, CDDN Continuum of Care Project

Psychoactive Medications. Alya Reeve, MD Carla Fedor, RN, CDDN Continuum of Care Project Psychoactive Medications Alya Reeve, MD Carla Fedor, RN, CDDN Continuum of Care Project PSYCHOACTIVE MEDICATIONS Definition: Any medication which has the capability to alter mood, anxiety, behavior or

More information

Polypharmacy 101. Acknowledgements. Disclosure. with special thanks to Jen Lehman, PharmD candidate

Polypharmacy 101. Acknowledgements. Disclosure. with special thanks to Jen Lehman, PharmD candidate Polypharmacy 101 Kimberly Brand, PharmD Acknowledgements Original presentation by Chris Cawood, PharmD, with special thanks to Jen Lehman, PharmD candidate Content Contributions: Stephanie Powell, PharmD

More information

Insomnia: Updates in Medical Management. Michael Newnam M.D.

Insomnia: Updates in Medical Management. Michael Newnam M.D. Insomnia: Updates in Medical Management Michael Newnam M.D. Sleep Neurobiology Delicate balance of excitatory and inhibitory neurotransmitters that control the switch between wakefulness and sleep Circadian

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Rexulti) Reference Number: CP.PMN.68 Effective Date: 11.05.15 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Abilify Maintena, Aristada, Aristada Initio) Reference Number: CP.PHAR.290 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid Coding Implications Revision Log

More information

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose

PAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,

More information

Fall Prevention in Hospice (A pharmacologic and nonpharmacologic approach)

Fall Prevention in Hospice (A pharmacologic and nonpharmacologic approach) Fall Prevention in Hospice (A pharmacologic and nonpharmacologic approach) Chinenye Emereole, Pharm.D. Clinical Pharmacist Hospice Pharmacy Solutions Objectives Assess and identify hospice patients who

More information

Integrating INTERACT into Interim Pharmacist Reviews

Integrating INTERACT into Interim Pharmacist Reviews Integrating INTERACT into Interim Pharmacist Reviews Chad R. Worz, Pharm.D. President, Medication Managers, LLC Adjunct Assistant Professor of Pharmacy Practice, University of Cincinnati, College of Pharmacy

More information

TOP APS DRUGS TRAZODONE BRAND NAMES: OLEPTRO, DESYREL (DIVIDOSE) & TRIALODINE

TOP APS DRUGS TRAZODONE BRAND NAMES: OLEPTRO, DESYREL (DIVIDOSE) & TRIALODINE trazodone TOP APS DRUGS TRAZODONE BRAND NAMES: OLEPTRO, DESYREL (DIVIDOSE) & TRIALODINE Pharmacodynamics study of what a drug does to the body Studies show that trazodone selectively inhibits neuronal

More information

NEW PATIENT QUESTIONNAIRE

NEW PATIENT QUESTIONNAIRE NEW PATIENT QUESTIONNAIRE PATIENT NAME: PRIMARY DOCTOR: DATE: REFERRING DOCTOR: Please show the location of your pain by drawing on the figures below: Pain History 1. WHERE IS YOUR PAIN LOCATED? 0 Low

More information

AHPCO Spring Conference 05/23/2014

AHPCO Spring Conference 05/23/2014 Psychotropic Drug Use: Documentation and Consent Lisa Cheney, R.N., B.S.N. Hospice R.N. Case Manager Hospice of the West Andrew Barrett, PharmD, BCPS Clinical Pharmacist HospiScript, a Catamaran Company

More information

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children

Judges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17

More information

What would you think?

What would you think? What would you think? Would you administer a medication to a patient if you were warned by the FDA that by giving it you have increased this resident s risk of death? Strategies in Psychoactive Medication

More information

APPENDIX E: HEALTHCARE PRACTITIONER- REPORTED REDUCTION OF PAIN MEDICATION

APPENDIX E: HEALTHCARE PRACTITIONER- REPORTED REDUCTION OF PAIN MEDICATION Contents Appendix E: Healthcare Practitioner-Reported Reduction of Pain Medication... E-1 Appendix E: Healthcare Practitioner- Reported Reduction of Pain Medication Note: Word choice and spellings have

More information

Full details and resource documents available:

Full details and resource documents available: Clinical & Regulatory News by Pharmerica Urinary Tract Infection (UTI) Second Most Common Cause of Hospital Readmission within 30 days UTIs are prevalent and account for up to 22% of infections in LTC,

More information

May 22, DAL: DAL SUBJECT: Hot Weather Advisory. Dear Administrator/Operator:

May 22, DAL: DAL SUBJECT: Hot Weather Advisory. Dear Administrator/Operator: May 22, 2013 DAL: DAL 13-11 SUBJECT: Hot Weather Advisory Dear Administrator/Operator: The New York State Department of Health would like to remind you of our expectations regarding the protection of Adult

More information

Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests

Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) University of Texas Health Science Center San Antonio Pharmacotherapy Education and Research Center (PERC) 7703 Floyd Curl Drive - MSC 6220 San

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Non-Benzodiazepine Insomnia Medications Reference Number: CP.HNMC.265 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder

More information

Psychotropic Medication Use in Dementia

Psychotropic Medication Use in Dementia Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,

More information

#55 PRESCRIBING AND MONITORING PSYCHI RIC MEDICATIONS

#55 PRESCRIBING AND MONITORING PSYCHI RIC MEDICATIONS - '_ ADMINISTRA TIVE/FISCAUCLINICAL/PHF POLICY AND PROCEDURES COUNTY OF SANTA BARBARA ALCOHOL, DRUG AND MENTAL HEAL TH SERVICES Section - QUALITY ASSURANCE Effective: 12/1/09 Policy- Director's Approval

More information

9/11/2012. Clare I. Hays, MD, CMD

9/11/2012. Clare I. Hays, MD, CMD Clare I. Hays, MD, CMD Review regulatory background for current CMS emphasis on antipsychotics Understand the risks and (limited) benefits of antipsychotic medications Review non-pharmacologic management

More information

Common Psychiatric Disorders at the End of Life

Common Psychiatric Disorders at the End of Life Common Psychiatric Disorders at the End of Life Allison E Jordan MD, HMDC Medical Director of Palliative Medicine Christian Hospital NE and Alton Memorial Hospital Associate Medical Director, BJC Hospice

More information

My Background. Presentation Outline. Common Psychiatric Disorders at the End of Life 9/13/2018

My Background. Presentation Outline. Common Psychiatric Disorders at the End of Life 9/13/2018 Common Psychiatric Disorders at the End of Life Allison E Jordan MD, HMDC Medical Director of Palliative Medicine Christian Hospital NE and Alton Memorial Hospital Associate Medical Director, BJC Hospice

More information

A Geriatrician s Perspective on Successful Aging. Ariel Green, MD, MPH Assistant Professor of Medicine

A Geriatrician s Perspective on Successful Aging. Ariel Green, MD, MPH Assistant Professor of Medicine A Geriatrician s Perspective on Successful Aging Ariel Green, MD, MPH Assistant Professor of Medicine 1 Disclosures Johns Hopkins Clinical Research Scholars Program American College of Cardiology Foundation

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Non-Benzodiazepine Insomnia Reference Number: CP.PMA_10.11.23 Effective Date: 07.16 Last Review Date: 04.18 Line of Business: Medicaid- Arizona (AHCS, CIC) Revision Log See Important Reminder

More information

med ed Copyright All rights reserved. No part of this publication can be reproduced without prior written consent of the authors.

med ed Copyright All rights reserved. No part of this publication can be reproduced without prior written consent of the authors. med ed Dr. Andrea Murphy, Assistant Professor, School of Nursing, Dalhousie University; Research Associate, Sun Life Financial Chair in Adolescent Mental Health Dr. David Gardner, Associate Professor,

More information

Using Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal. Alan Poling, Ph.D., BCBA-D Western Michigan University

Using Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal. Alan Poling, Ph.D., BCBA-D Western Michigan University Using Drugs to Improve the Behavior of People with Autism: A Skeptical Appraisal Alan Poling, Ph.D., BCBA-D Western Michigan University In a 2010 study of 60,641 children Mandell et al. found that: 56%

More information

LAGUNA BEHAVIORAL Crown Valley Parkway, Suite 140 Phone: (949) Laguna Niguel, CA Fax: (949)

LAGUNA BEHAVIORAL Crown Valley Parkway, Suite 140 Phone: (949) Laguna Niguel, CA Fax: (949) NEW PATIENT INFORMATION - ADULTS CLIENT INFORMATION Patient s Name: Today s Date: Other Names: Date of Birth: Age: Address: Street Apartment City State ZIP E-mail Address: May we contact you via e-mail

More information